GANX
Gain Therapeutics Inc

2,480
Mkt Cap
$69.62M
Volume
1.13M
52W High
$4.34
52W Low
$1.41
PE Ratio
-3.11
GANX Fundamentals
Price
$1.99
Prev Close
$1.81
Open
$1.81
50D MA
$2.97
Beta
1.14
Avg. Volume
2.05M
EPS (Annual)
-$0.892
P/B
12.11
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6%
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Gain Therapeutics Shares Early Phase 1b Data: GT-02287 Shows UPDRS Gains, Key PD Biomarker Drop
Gain Therapeutics (NASDAQ:GANX) highlighted early clinical and biomarker findings from the first 90 days of its ongoing Phase 1b open-label study evaluating GT-02287 in people with Parkinson's...
MarketBeat·14d ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven brokerages that are currently covering the firm, Marketbeat reports. One...
MarketBeat·19d ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totaling 2,073,310 shares, a growth of...
MarketBeat·23d ago
News Placeholder
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·29d ago
News Placeholder
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Friday...
MarketBeat·1mo ago
News Placeholder
Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?
Here is how Enhabit (EHAB) and Gain Therapeutics, Inc. (GANX) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy
Does Gain Therapeutics, Inc. (GANX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·1mo ago
News Placeholder
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat...
MarketBeat·1mo ago
News Placeholder
FY2025 Earnings Forecast for GANX Issued By HC Wainwright
Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - Stock analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for Gain Therapeutics in a report released on Monday...
MarketBeat·2mo ago
<
1
2
...
>

Latest GANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.